REDWOOD CITY, Calif.–(BUSINESS WIRE)–Mar. 3, 2025– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and…Original Article
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
